23:38:18 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2024-10-24 Kvartalsrapport 2024-Q3
2024-08-23 Kvartalsrapport 2024-Q2
2024-06-20 Ordinarie utdelning TOL 0.00 SEK
2024-06-19 Årsstämma 2024
2024-05-20 Kvartalsrapport 2024-Q1
2024-02-23 Bokslutskommuniké 2023
2023-10-27 Kvartalsrapport 2023-Q3
2023-08-25 Kvartalsrapport 2023-Q2
2023-06-08 Ordinarie utdelning TOL 0.00 SEK
2023-06-07 Årsstämma 2023
2023-05-03 Kvartalsrapport 2023-Q1
2023-02-24 Bokslutskommuniké 2022
2022-10-28 Kvartalsrapport 2022-Q3
2022-08-26 Kvartalsrapport 2022-Q2
2022-06-07 Ordinarie utdelning TOL 0.00 SEK
2022-06-03 Årsstämma 2022
2022-05-06 Kvartalsrapport 2022-Q1
2022-02-25 Bokslutskommuniké 2021
2021-10-29 Kvartalsrapport 2021-Q3
2021-09-16 Extra Bolagsstämma 2021
2021-08-27 Kvartalsrapport 2021-Q2
2021-06-07 Ordinarie utdelning TOL 0.00 SEK
2021-06-04 Årsstämma 2021
2021-05-06 Kvartalsrapport 2021-Q1
2021-02-25 Bokslutskommuniké 2020
2020-11-02 Kvartalsrapport 2020-Q3
2020-08-10 Kvartalsrapport 2020-Q2
2020-06-15 Ordinarie utdelning TOL 0.00 SEK
2020-06-12 Årsstämma 2020
2020-05-11 Kvartalsrapport 2020-Q1
2020-02-26 Bokslutskommuniké 2019
2019-11-18 Kvartalsrapport 2019-Q3
2019-08-26 Kvartalsrapport 2019-Q2
2019-06-14 Ordinarie utdelning TOL 0.00 SEK
2019-06-13 Årsstämma 2019
2019-05-10 Kvartalsrapport 2019-Q1
2019-02-26 Bokslutskommuniké 2018
2018-11-26 Kvartalsrapport 2018-Q3
2018-08-24 Kvartalsrapport 2018-Q2
2018-06-18 Ordinarie utdelning TOL 0.00 SEK
2018-06-15 Årsstämma 2018
2018-05-11 Kvartalsrapport 2018-Q1
2018-02-13 Bokslutskommuniké 2017
2018-02-05 Extra Bolagsstämma 2017
2017-12-08 Extra Bolagsstämma 2017
2017-11-17 Kvartalsrapport 2017-Q3
2017-08-24 Kvartalsrapport 2017-Q2
2017-06-12 Ordinarie utdelning TOL 0.00 SEK
2017-06-09 Årsstämma 2017
2017-05-12 Kvartalsrapport 2017-Q1
2017-02-23 Bokslutskommuniké 2016
2016-11-14 Kvartalsrapport 2016-Q3
2016-08-25 Kvartalsrapport 2016-Q2
2016-06-10 Årsstämma 2016
2016-05-25 Kvartalsrapport 2016-Q1
2016-05-11 Ordinarie utdelning TOL 0.00 SEK
2016-02-24 Bokslutskommuniké 2015

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
Toleranzia är ett forskningsbolag. Bolagets affärsinriktning återfinns inom utveckling av läkemedelskandidater för behandling av autoimmuna sjukdomar. Bolaget har utvecklat en plattformsteknologi med fokus mot muskelsjukdomen myastenia gravis. Utöver har teknologin använts i övriga områden som diabetes och multipel skleros. Forskningssamarbeten sker i samarbete med externa partners inom arbetsområdet. Huvudkontoret ligger i Göteborg.
2022-03-28 10:00:00

Toleranzia AB (publ) ("Toleranzia" or the "Company") today announces that the Company has taken additional steps to secure access to the materials required to complete the scale-up of production and large-scale manufacturing of its drug candidate TOL2. The shortage of materials caused by the COVID-19 pandemic has previously led to significant uncertainty as to when the first batch of TOL2 for the clinical trial could be produced. Now that the Company has succeeded in finding an additional supplier and has ordered, on behalf of its production partner 3P Biopharmaceuticals, all the purification material needed for the large-scale production, the prospects of being able to start the study in the second half of 2023 in accordance with the communicated schedule are strengthened.

Toleranzia announced in November 2021 that the start of the Company's planned first clinical study of its drug candidate TOL2 will be delayed due to a lack of materials for large-scale production. The shortage was due to the fact that the material necessary for the purification of TOL2 is also used in the production of vaccines against COVID-19.
 
Since then, Toleranzia has been evaluating options to complete production as quickly as possible. Analyses carried out by the company show unequivocally that the purification material from the Uppsala-based company Bio-Works is of a very high quality, fully comparable to that of other suppliers. As Bio-Works can also guarantee short delivery times, Toleranzia has placed an order, securing the supply of the entire requirement of the critical purification material for the large-scale purification process, for delivery to its manufacturing partner 3P Biopharmaceuticals.
 
"In addition to being able to use this time to optimize the upcoming clinical trial with TOL2, it is gratifying and a relief that we have now been able to find and evaluate an alternative supplier that will ensure our material needs for the large-scale production of TOL2. Our partner 3P Biopharmaceuticals will now be able to continue the scale-up of production and we are working focused to start the clinical trial in the second half of 2023 as planned," said Toleranzia's CEO, Charlotte Fribert.
 
For further information, please contact:
Charlotte Fribert - CEO, Toleranzia
Tel: +46 763 19 98 98
Email: charlotte.fribert@toleranzia.com
 
About Toleranzia AB (publ)
Toleranzia AB (publ) develops drugs that harness the power of the immune system for the treatment of autoimmune orphan diseases. The drugs, which target the cause of the disease, can cure or significantly alleviate the disease and not, like current treatments, merely reduce the symptoms. They have the potential to be the first long-acting or curative therapies that act specifically on the underlying cause of the autoimmune orphan disease for which they are being developed. Toleranzia's shares are listed on the Nasdaq First North Growth Market and Mangold Fondkommission AB, 08-503 015 50, CA@mangold.se, is the Company's Certified Adviser.